| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
1 | AN ACT concerning criminal law.
| |||||||||||||||||||
2 | Be it enacted by the People of the State of Illinois,
| |||||||||||||||||||
3 | represented in the General Assembly:
| |||||||||||||||||||
4 | Section 5. The Illinois Controlled Substances Act is | |||||||||||||||||||
5 | amended by changing Section 316 as follows:
| |||||||||||||||||||
6 | (720 ILCS 570/316)
| |||||||||||||||||||
7 | Sec. 316. Prescription Monitoring Program. | |||||||||||||||||||
8 | (a) The Department must provide for a
Prescription | |||||||||||||||||||
9 | Monitoring Program for Schedule II, III, IV, and V controlled | |||||||||||||||||||
10 | substances that includes the following components and | |||||||||||||||||||
11 | requirements:
| |||||||||||||||||||
12 | (1) The
dispenser must transmit to the
central | |||||||||||||||||||
13 | repository, in a form and manner specified by the | |||||||||||||||||||
14 | Department, the following information:
| |||||||||||||||||||
15 | (A) The recipient's name and address.
| |||||||||||||||||||
16 | (B) The recipient's date of birth and gender.
| |||||||||||||||||||
17 | (C) The national drug code number of the controlled
| |||||||||||||||||||
18 | substance
dispensed.
| |||||||||||||||||||
19 | (D) The date the controlled substance is | |||||||||||||||||||
20 | dispensed.
| |||||||||||||||||||
21 | (E) The quantity of the controlled substance | |||||||||||||||||||
22 | dispensed and days supply.
| |||||||||||||||||||
23 | (F) The dispenser's United States Drug Enforcement |
| |||||||
| |||||||
1 | Administration
registration number.
| ||||||
2 | (G) The prescriber's United States Drug | ||||||
3 | Enforcement Administration
registration number.
| ||||||
4 | (H) The dates the controlled substance | ||||||
5 | prescription is filled. | ||||||
6 | (I) The payment type used to purchase the | ||||||
7 | controlled substance (i.e. Medicaid, cash, third party | ||||||
8 | insurance). | ||||||
9 | (J) The patient location code (i.e. home, nursing | ||||||
10 | home, outpatient, etc.) for the controlled substances | ||||||
11 | other than those filled at a retail pharmacy. | ||||||
12 | (K) Any additional information that may be | ||||||
13 | required by the department by administrative rule, | ||||||
14 | including but not limited to information required for | ||||||
15 | compliance with the criteria for electronic reporting | ||||||
16 | of the American Society for Automation and Pharmacy or | ||||||
17 | its successor. | ||||||
18 | (2) The information required to be transmitted under | ||||||
19 | this Section must be
transmitted not later than the end of | ||||||
20 | the next business day after the date on which a
controlled | ||||||
21 | substance is dispensed, or at such other time as may be | ||||||
22 | required by the Department by administrative rule.
| ||||||
23 | (3) A dispenser must transmit the information required | ||||||
24 | under this Section
by:
| ||||||
25 | (A) an electronic device compatible with the | ||||||
26 | receiving device of the
central repository;
|
| |||||||
| |||||||
1 | (B) a computer diskette;
| ||||||
2 | (C) a magnetic tape; or
| ||||||
3 | (D) a pharmacy universal claim form or Pharmacy | ||||||
4 | Inventory Control form;
| ||||||
5 | (4) The Department may impose a civil fine of up to | ||||||
6 | $100 per day for willful failure to report controlled | ||||||
7 | substance dispensing to the Prescription Monitoring | ||||||
8 | Program. The fine shall be calculated on no more than the | ||||||
9 | number of days from the time the report was required to be | ||||||
10 | made until the time the problem was resolved, and shall be | ||||||
11 | payable to the Prescription Monitoring Program.
| ||||||
12 | (b) The Department, by rule, may include in the | ||||||
13 | Prescription Monitoring Program certain other select drugs | ||||||
14 | that are not included in Schedule II, III, IV, or V. The | ||||||
15 | Prescription Monitoring Program does not apply to
controlled | ||||||
16 | substance prescriptions as exempted under Section
313.
| ||||||
17 | (c) The collection of data on select drugs and scheduled | ||||||
18 | substances by the Prescription Monitoring Program may be used | ||||||
19 | as a tool for addressing oversight requirements of long-term | ||||||
20 | care institutions as set forth by Public Act 96-1372. Long-term | ||||||
21 | care pharmacies shall transmit patient medication profiles to | ||||||
22 | the Prescription Monitoring Program monthly or more frequently | ||||||
23 | as established by administrative rule. | ||||||
24 | (d) The Department of Human Services shall appoint a | ||||||
25 | full-time Clinical Director of the Prescription Monitoring | ||||||
26 | Program. |
| |||||||
| |||||||
1 | (e) (Blank). | ||||||
2 | (f) Within one year of the effective date of this | ||||||
3 | amendatory Act of the 100th General Assembly, the Department | ||||||
4 | shall adopt rules requiring all Electronic Health Records | ||||||
5 | Systems to interface with the Prescription Monitoring Program | ||||||
6 | application program on or before January 1, 2021 to ensure that | ||||||
7 | all providers have access to specific patient records during | ||||||
8 | the treatment of their patients. These rules shall also address | ||||||
9 | the electronic integration of pharmacy records with the | ||||||
10 | Prescription Monitoring Program to allow for faster | ||||||
11 | transmission of the information required under this Section. | ||||||
12 | The Department shall establish actions to be taken if a | ||||||
13 | prescriber's Electronic Health Records System does not | ||||||
14 | effectively interface with the Prescription Monitoring Program | ||||||
15 | within the required timeline. | ||||||
16 | (g) The Department, in consultation with the Advisory | ||||||
17 | Committee, shall adopt rules allowing licensed prescribers or | ||||||
18 | pharmacists who have registered to access the Prescription | ||||||
19 | Monitoring Program to authorize a designee to consult the | ||||||
20 | Prescription Monitoring Program on their behalf. The rules | ||||||
21 | shall include reasonable parameters concerning a | ||||||
22 | practitioner's authority to authorize a designee, and the | ||||||
23 | eligibility of a person to be selected as a designee. | ||||||
24 | (Source: P.A. 99-480, eff. 9-9-15; 100-564, eff. 1-1-18.)
|